Journal of microencapsulation最新文献

An update on nanoformulations with FDA approved drugs for female reproductive cancer.

IF 3 4区医学

Journal of microencapsulation Pub Date : 2025-03-20 DOI: 10.1080/02652048.2025.2474457

Mahima Raj, Abha Meena, Richa Seth, Anurag Mathur, Suaib Luqman

{"title":"An update on nanoformulations with FDA approved drugs for female reproductive cancer.","authors":"Mahima Raj, Abha Meena, Richa Seth, Anurag Mathur, Suaib Luqman","doi":"10.1080/02652048.2025.2474457","DOIUrl":"https://doi.org/10.1080/02652048.2025.2474457","url":null,"abstract":"Female reproductive cancers, including ovarian, cervical, breast, gestational trophoblastic and endometrial cancer, present significant challenges in therapy and patient prognosis. Conventional chemotherapy often lacks selectivity, leading to systemic toxicity and reduced treatment efficacy. Nanotechnology has emerged as a promising approach to improve drug delivery and therapeutic outcomes. Encapsulation of FDA-approved drugs within nanocarriers such as liposomes, polymeric nanoparticles, and lipid nanoparticles enables controlled drug release, reduces off-target effects, and enhances drug accumulation at tumor sites. This targeted delivery minimizes damage to healthy tissues and improves patient survival rates. Additionally, nanoformulations facilitate combination therapy, overcoming drug resistance and maximizing therapeutic efficacy. Despite promising results, challenges like scalability, reproducibility, and regulatory approvals hinder widespread clinical applications. Developing personalized nanoformulations tailored to individual patient profiles offers potential for precision cancer therapy. This study explores the role of nanoformulations in enhancing the therapeutic potential of FDA-approved drugs for treating female reproductive cancers.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"1-34"},"PeriodicalIF":3.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel formulation of curcumin-loaded chlorhexidine drug combined with gold nanoparticles for effective therapeutic agent against urinary tract infections.

IF 3 4区医学

Journal of microencapsulation Pub Date : 2025-03-01 Epub Date: 2025-02-13 DOI: 10.1080/02652048.2025.2457667

Jian Kang, Yanqing Tong

{"title":"Novel formulation of curcumin-loaded chlorhexidine drug combined with gold nanoparticles for effective therapeutic agent against urinary tract infections.","authors":"Jian Kang, Yanqing Tong","doi":"10.1080/02652048.2025.2457667","DOIUrl":"10.1080/02652048.2025.2457667","url":null,"abstract":"Aim: This study investigates a novel treatment for urinary tract infections (UTIs) caused by Staphylococcus aureus, Escherichia coli, and Klebsiella pathogenic bacterial strains.Methods: The Cur/Chx/Au composite matrix was synthesised in one pot by solution reduction and examined for functional groups and surface morphology by FT-IR, UV-DRS, HR-TEM, and TGA. In vitro, microbial growth inhibition evaluation and pathogen biofilm studies assessed the composite's antibacterial capacity.Results: Cur/Chx/Au exhibit mean diameter from 30 ± 5.2 nm, PDI 0.50 ± 0.05, and a zeta potential of -9.56 ± 1.84. The inhibition zones for S. aureus and E. coli were 16 ± 1.2 mm and 14 ± 0.8 mm, respectively, with an anti-inflammatory inhibition rate of 89.96%. The composite material's biocompatibility was further tested utilising in-vitro MTT, cell proliferation, and wound scratch assays in NHI 3T3 cells.Conclusion: Our findings demonstrate that the combination of Cur/Chx/Au composite matrix is a promising formulation for UTI treatment.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"177-190"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isolation and characterization of medicinal plant-based extracellular vesicles as nano delivery systems for ascorbic acid. 抗坏血酸纳米递送系统药用植物细胞外囊泡的分离与表征。

IF 3 4区医学

Journal of microencapsulation Pub Date : 2025-03-01 Epub Date: 2024-12-23 DOI: 10.1080/02652048.2024.2443430

Zainab Muhammad, Suleiman A Muhammad, Abdullahi Y Abbas, Mohammed Achor, Samson A Adeyemi, Yahya E Choonara, Yusuf Saidu, Lawal S Bilbis

{"title":"Isolation and characterization of medicinal plant-based extracellular vesicles as nano delivery systems for ascorbic acid.","authors":"Zainab Muhammad, Suleiman A Muhammad, Abdullahi Y Abbas, Mohammed Achor, Samson A Adeyemi, Yahya E Choonara, Yusuf Saidu, Lawal S Bilbis","doi":"10.1080/02652048.2024.2443430","DOIUrl":"10.1080/02652048.2024.2443430","url":null,"abstract":"Aim: Plant-derived extracellular vesicles (EVs) are natural nanovesicles for drug delivery. This study isolated and characterised EVs from medicinal plants as delivery vehicles.Methods: Precipitation method was employed for the isolation and characterised using DLS, SEM, and TEM. The encapsulation efficiency (EE) and antioxidant activity of ascorbic acid (AA)-EVs were evaluated.Results: The total yields of lyophilised vesicles per weight of the sample were 6.0, 8.6 and 9.2 mg/g for garlic, turmeric and ginger, respectively. Mean size of garlic-derived EVs, ginger-derived EVs, and turmeric-derived EVs were 101.0 ± 6.7, 226.4 ± 62.2 and 90.7 ± 2.5 nm, respectively. The zeta potential of the EVs was between -33.2 ± 10.9 and -28.8 ± 8.43 mV. Spherical morphology of the nanovesicles was confirmed by SEM and TEM. The EE of the EVs was between 78.1 ± 2.8% and 87.2 ± 1.4%.Conclusion: Overall, the antioxidant activity of AA-loaded EVs was better compared to free AA. This study provides evidence that these medicinal plants are rich sources for developing nanotherapeutics.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"120-131"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the antimicrobial and anticancer potential of a modified silver nanoparticle-impregnated carrier system. 一种改性纳米银浸渍载体体系的抗菌和抗癌潜力评价。

IF 3 4区医学

Journal of microencapsulation Pub Date : 2025-03-01 Epub Date: 2024-12-24 DOI: 10.1080/02652048.2024.2443437

Ebru Kilicay, Ebru Erdal, Özge Kübra Karadag, Baki Hazer

{"title":"Evaluation of the antimicrobial and anticancer potential of a modified silver nanoparticle-impregnated carrier system.","authors":"Ebru Kilicay, Ebru Erdal, Özge Kübra Karadag, Baki Hazer","doi":"10.1080/02652048.2024.2443437","DOIUrl":"10.1080/02652048.2024.2443437","url":null,"abstract":"This study aimed to develop silver nanoparticles embedded in poly(ricinoleic acid)-poly(methyl methacrylate)-poly(ethylene glycol) (AgNPsPRici-PMMA-PEG) nanoparticles (NPs) containing caffeic acid (Caff) and tetracycline hydrochloride (TCH) for treating infections and cancer in bone defects. The block copolymers were synthesised via free radical polymerisation. NPs were prepared using the solvent evaporation method and characterised by FTIR, HNMR, SEM, DSC, TGA, and DLS. Drug loading (LE), encapsulation efficiency (EE), antimicrobial activity, cytotoxicity, and in vitro release studies were conducted. The NPs exhibited a size of 198 ± 2.89 nm, a narrow size distribution (PDI < 0.1), and a zeta potential of -27.5 ± 0.13 mV. The EE of Caff were 73 ± 0.09% w/w and 78 ± 0.32% w/w. Caff NPs showed prolonged release (69 ± 0.23% w/w), cytotoxicity with the cell viability of 66.85 ± 10.51% in SaOS cells, and antimicrobial zones ranging from 1.5 ± 0.3 to 4.2 ± 0.2 mm. TCH-Caff-AgNPsPRici-PMMA-PEG NPs exhibited promising therapeutic potential for infection and cancer treatment in bone defects.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"142-160"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Encapsulation of anti-VEGF nanobody into niosome nanoparticles: a novel approach to enhance circulation half life and efficacy. 将抗vegf纳米体包封到纳米粒中：一种提高循环半衰期和疗效的新方法。

IF 3 4区医学

Journal of microencapsulation Pub Date : 2025-03-01 Epub Date: 2024-12-23 DOI: 10.1080/02652048.2024.2443435

Mohsen Chiani, Raha Abedini, Reza Ahangari-Cohan, Mahdi Behdani, Seyed Mahmoud Barzi, Nastaran Mohseni, Fatemeh Kazemi-Lomedasht

{"title":"Encapsulation of anti-VEGF nanobody into niosome nanoparticles: a novel approach to enhance circulation half life and efficacy.","authors":"Mohsen Chiani, Raha Abedini, Reza Ahangari-Cohan, Mahdi Behdani, Seyed Mahmoud Barzi, Nastaran Mohseni, Fatemeh Kazemi-Lomedasht","doi":"10.1080/02652048.2024.2443435","DOIUrl":"10.1080/02652048.2024.2443435","url":null,"abstract":"This study aimed to encapsulate an anti-VEGF nanobody (Nb) within niosome nanoparticles (NNPs) to enhance its circulation half life. Key parameters such as encapsulation efficiency, stability, Nb release, cytotoxicity, and cell migration inhibition in HUVEC cells were evaluated, along with pharmacokinetic studies in mice. Nb-loaded NNPs (Nb-NNPs) were successfully prepared with an encapsulation efficiency of 78.3 ± 3.2% and demonstrated stability over one month. In vitro assays revealed that Nb-NNPs enhanced cytotoxicity and significantly reduced cell migration in HUVEC cells compared to free Nb (P < 0.05). Pharmacokinetic studies in mice demonstrated a dramatically reduced elimination rate constant (0.025 h-1 vs. 0.843 h-1) and an extended terminal half life (27.721 h vs. 0.822 h), indicating slower clearance and prolonged systemic presence. In conclusion, these findings underscore the potential of Nb-NNPs to provide sustained and potent therapeutic effects, contributing valuable insights for advancing targeted therapeutic strategies.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"132-141"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimisation and evaluation of long circulating Ru-SLNs carrier for targeting melanoma cells. 靶向黑色素瘤细胞的长循环ru - sln载体的优化与评价。

IF 3 4区医学

Journal of microencapsulation Pub Date : 2025-03-01 Epub Date: 2024-12-24 DOI: 10.1080/02652048.2024.2443436

Hitesh Kumar Dewangan, Kamal Shah, Anil Kumar Vadaga, Manisha Veer, Perwez Alam

{"title":"Optimisation and evaluation of long circulating Ru-SLNs carrier for targeting melanoma cells.","authors":"Hitesh Kumar Dewangan, Kamal Shah, Anil Kumar Vadaga, Manisha Veer, Perwez Alam","doi":"10.1080/02652048.2024.2443436","DOIUrl":"10.1080/02652048.2024.2443436","url":null,"abstract":"The aim of study was to prepared and evaluated rutin-loaded solid-lipid-nanoparticles (Ru-SLNs) gel for treatment of melanoma cells. SLNs were prepared by ultrasonication method through optimisation and evaluated their mean-diameter, PDI, zeta-potential, morphology, entrapment-efficiency, drug-loading, interaction by FTIR, in vitro skin permeation, stability, antioxidant/MTT assay and fluorescence microscopic. Further developed Ru-SLNs was incorporated into gel and characterised their physicochemical properties, drug contents, in vitro diffusion, ex vivo permeation and retention studies in human cadaver skin. Optimised Ru-SLNs batch showed 556.4 ± 2.6 nm mean-diameter, -21.9 mV zeta-potential, 94.8 ± 04% entrapment-efficiency, 62.3 ± 29% loading, and 86.63% release after 6 hrs. MTT assay showed, Ru-SLNs have 15.37 times more effectiveness against melanoma cells, while fluorescence microscopy confirmed the cellular uptake over time. Gel based Ru-SLNs, have reduction in flux across skin, indicating a sustained release of rutin and higher retention within the deeper epidermis layer. Finally, Ru-SLNs based gel exhibited promising potential and effectively targeting to skin's epidermal layer for melanoma cells.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"107-119"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimisation of albendazole delivery and assessment of anticancer potential in hepatocellular carcinoma (HepG2 cells) using surface modified nanostructured lipid carriers. 利用表面修饰的纳米结构脂质载体优化阿苯达唑在肝细胞癌（HepG2细胞）中的递送和抗癌潜力评估。

IF 3 4区医学

Journal of microencapsulation Pub Date : 2025-03-01 Epub Date: 2025-01-17 DOI: 10.1080/02652048.2025.2451848

Walid Anwar, Abdulsalam M Kassem, Ayman Salama, Mohamed F Zidan, Ahmed H Ibrahim, Ibrahim A Elbahwy, Elsaied H Barakat, Tarek M Faris, Maged K Elsayad, Ahmed M Samy, Mahmoud M A Elsayed, Abdelaziz E Abdelaziz

{"title":"Optimisation of albendazole delivery and assessment of anticancer potential in hepatocellular carcinoma (HepG2 cells) using surface modified nanostructured lipid carriers.","authors":"Walid Anwar, Abdulsalam M Kassem, Ayman Salama, Mohamed F Zidan, Ahmed H Ibrahim, Ibrahim A Elbahwy, Elsaied H Barakat, Tarek M Faris, Maged K Elsayad, Ahmed M Samy, Mahmoud M A Elsayed, Abdelaziz E Abdelaziz","doi":"10.1080/02652048.2025.2451848","DOIUrl":"10.1080/02652048.2025.2451848","url":null,"abstract":"This study evaluated albendazole (ABZ) nanostructured lipid carriers (NLCs) for hepatocellular carcinoma treatment. ABZ-NLCs were prepared using emulsification-ultrasonication and optimised using a Box-Behnken design. Independent variables-lipids concentration (X1), surfactant concentration (X2), and sonication duration (X3)-were assessed for their effect on mean diameter (Y1), PDI (Y2), and entrapment efficiency (Y3). The optimised formulation exhibited a mean diameter of 166.13 ± 3.72 nm, a PDI of 0.17 ± 0.01, a zeta potential of -39.86 ± 1.84 mV, an entrapment efficiency of 94.25 ± 6.12%, and a loading capacity of 99.93 ± 7.15 mg/g. Following chitosan coating (ABZ-CS-NLCs), all parameters were maintained, and the zeta potential developed to +24.61 ± 1.32 mV, improving cellular interaction. The cytotoxicity assays revealed that ABZ-CS-NLCs were more effective than uncoated NLCs and free ABZ, with an IC50 value of 8.89 μM in HepG2 cells. Overall, ABZ-CS-NLCs demonstrate a promising and effective delivery platform for targeted hepatic cancer therapy.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"161-176"},"PeriodicalIF":3.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preparation, characterisation, anticancer potential and safety evaluation of a soy lecithin phytosome delivery system loaded with constituents from Barleria lupulina.

IF 3 4区医学

Journal of microencapsulation Pub Date : 2025-02-24 DOI: 10.1080/02652048.2025.2467046

Sabyasachi Banerjee, Shibangi Mukhopadhyay, Avik Das, Subhasis Banerjee, Sankhadip Bose, Santanu Banerjee, Nicolette Casarcia, Anupam Bishayee

{"title":"Preparation, characterisation, anticancer potential and safety evaluation of a soy lecithin phytosome delivery system loaded with constituents from Barleria lupulina.","authors":"Sabyasachi Banerjee, Shibangi Mukhopadhyay, Avik Das, Subhasis Banerjee, Sankhadip Bose, Santanu Banerjee, Nicolette Casarcia, Anupam Bishayee","doi":"10.1080/02652048.2025.2467046","DOIUrl":"https://doi.org/10.1080/02652048.2025.2467046","url":null,"abstract":"In this study, antineoplastic effects of a novel soy lecithin-based phytosome drug delivery system containing Barleria lupulina Lindl. extract (BLSP) was evaluated. BLSP was prepared using the thin-film hydration method and analysed using energy-dispersive X-ray spectroscopy, scanning electron microscopy, X-ray diffraction, and Zetasizer technique. Phytosomes showed a mean-diameter of 135 ± 0.29 nm, zeta potential of -56 ± 1.16 mV, and entrapment efficiency of 57.24 ± 0.12%. The drug release profiles exhibited a two-phase pattern with a protracted and sustained release after the first release. BLSP had a cytotoxic potential against MCF-7 breast and HeLa cervical cancers and demonstrated a concentration-dependent reduction of reactive oxygen species and mitochondrial membrane potential. BLSP caused upregulation of B-cell lymphoma-2-associated-X protein, caspase-8, caspase-9, and cluster of differentiation-95, and downregulation of B-cell lymphoma-2. The in vivo toxicity study showed the safety of BLSP. Overall, BLSP has demonstrated potential as a promising formulation for delivering B. lupulina phytoconstituents to treat breast and cervical cancer.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"1-21"},"PeriodicalIF":3.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gadolinium (Gd)-based nanostructures as dual-armoured materials for microbial therapy and cancer theranostics.

IF 3 4区医学

Journal of microencapsulation Pub Date : 2025-02-24 DOI: 10.1080/02652048.2025.2469259

Nadhir N A Jafar, Junainah Abd Hamid, Farag M A Altalbawy, Pawan Sharma, Abhishek Kumar, Shirin Shomurotova, Rafid Jihad Albadr, Kamil K Atiyah Altameemi, Hawraa Mahdi Saleh, Fakhri Alajeeli, Ahmed Mohammed Ahmed, Irfan Ahmad, Imad Ibrahim Dawood

引用次数: 0

Her-2 nanobody modified cisplatin nanoparticles for precise chemotherapy of colon cancer.

IF 3 4区医学

Journal of microencapsulation Pub Date : 2025-02-20 DOI: 10.1080/02652048.2025.2467060

Weina Liang, Yan Zhang, Jianpeng Li, Chenglin Ji, Xuexin Jiang

{"title":"Her-2 nanobody modified cisplatin nanoparticles for precise chemotherapy of colon cancer.","authors":"Weina Liang, Yan Zhang, Jianpeng Li, Chenglin Ji, Xuexin Jiang","doi":"10.1080/02652048.2025.2467060","DOIUrl":"https://doi.org/10.1080/02652048.2025.2467060","url":null,"abstract":"Construct a Her-2 nanobody modified nanoplatform as a versatile carrier of cisplatin and evaluate its anti-tumour effects. Size, morphology, cellular uptake, in vitro release, cell viability, bio-distribution and antitumor efficacy were respectively measured by dynamic light scattering, transmission electron microscopy, confocal microscopy, HPLC, MTT assay, ICP-Mass and tumour volume. Nb-CDDP NPs was prepared with average diameter 60.4 ± 8.4 nm, PDI 0.2 ± 0.02, Zeta potential -35.74 mV, entrapment efficiency 89.5%±0.8% and drug loading 28.7%±1.3% (w/w). From which cisplatin could release more rapidly in acidic solution. NPs could be easily phagocytised and exhibited stronger cytotoxic effect in HCT-116 cells with IC50 1.46 ± 0.019 μg/mL. The concentration of Nb-CDDP NPs in tumour and its inhibition ratio on tumour volume were both higher than without Nb modification, with hardly any influence on body weight. This cisplatin nanoplatform exhibits exceptional properties and high targeting anti-tumour efficacy in colon cancer cells and mice, which maybe provide a promising strategy for precise chemotherapy.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"1-9"},"PeriodicalIF":3.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0